Diffuse large B-cell lymphoma
Conditions
Interventions
study group:Teniposide 60mg/m^2 D1-3
Rituximab 375mg/m^2 D0
cyclophosphamide 750mg/m^2
Sponsors
The first affiliated hospital Zhejiang University school of medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. According to the fifth edition of the WHO classification of lymphohematopoietic system tumors, the patient was pathologically diagnosed with diffuse large B-cell lymphoma; 2. Age 18-65 years old; 3. Have not received chemotherapy and radiotherapy; 4. Physical condition (ECOG. score 0-2 points 5. CNS-IPI score of 4-6 points, involving testicles, breast, tumor tissues CD5 or intravascular large B patients at the time of initial diagnosis; 6. PET-CT or CT/MRI showing at least one two-dimensional measurable lesion (longest diameter> 1.5cm.; 7. Women of childbearing age must be confirmed by a pregnancy test that they are not pregnant, and are willing to take effective measures to prevent pregnancy during the test period and within >=12 months after the last dose; Pregnant and lactating females cannot participate; All male subjects used contraception during the trial period and within >=3 months after the last dose; 8. Can provide informed consent, can understand and comply with the requirements of the study.
Exclusion criteria
Exclusion criteria: 1. Have a serious mental illness; 2. Central nervous system involvement; 3. History of other active tumors 4. Pregnant or lactating women 5. Inability to understand or follow the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year central nervous system recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall response rate;Complete response rate;Partial response rate;Overall survival ;Progression-Free Survival;Safety; | — |
Countries
China
Contacts
Public ContactTong Hongyan
The first affiliated hospital Zhejiang University school of medicine
Outcome results
None listed